drugset / Trial / NCT01486238

Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study

NCT01486238

Phase 4 Completed 72 enrolled Valley Retina Institute
RandomizedParallel-groupDouble-blindTreatment

Summary

Intravitreal injections of pegaptanib every 4 weeks will be efficacious in treating Diabetic Macular Edema (DME), as compared to injections every 6 weeks.

Timeline

Start
2009-04
Primary completion
2011-07
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject pegaptanib sodium Aptamer 0.3 mg Intravitreal